Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Baxter
McKesson
Harvard Business School

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for abraxane

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug abraxane?

abraxane is an investigational drug.

There have been 370 clinical trials for abraxane. The most recent clinical trial was a Phase 3 trial, which was initiated on March 12th 2018.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Breast Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Celgene Corporation, National Cancer Institute (NCI), and Celgene.

There is one US patent protecting this investigational drug and fourteen international patents.

Recent Clinical Trials for abraxane
TitleSponsorPhase
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic CancerLexicon PharmaceuticalsPhase 2
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic CancerEmory UniversityPhase 2
Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A)Merck Sharp & Dohme Corp.Phase 2

See all abraxane clinical trials

Clinical Trial Summary for abraxane

Top disease conditions for abraxane
Top clinical trial sponsors for abraxane

See all abraxane clinical trials

US Patents for abraxane

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
abraxane   Start Trial Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
abraxane   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
abraxane   Start Trial 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors Vernalis (R&D) Limited (Winnersh, GB)   Start Trial
abraxane   Start Trial Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof Dana-Farber Cancer Institute, Inc. (Boston, MA) Beth Israel Deaconess Medical Center, Inc. (Boston, MA)   Start Trial
abraxane   Start Trial Anti-cancer agents and preparation thereof Purdue Research Foundation (West Lafayette, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for abraxane

Drugname Country Document Number Estimated Expiration Related US Patent
abraxane Australia 2012322660 2031-10-11   Start Trial
abraxane Australia 2017228527 2031-10-11   Start Trial
abraxane Canada 2851788 2031-10-11   Start Trial
abraxane European Patent Office 2766355 2031-10-11   Start Trial
abraxane World Intellectual Property Organization (WIPO) 2013055949 2031-10-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Baxter
McKinsey
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.